Observational study of pimecrolimus 1% cream for prevention of transcutaneous sensitization in children with atopic dermatitis during their first year of life.

Autor:	Murashkin NN; National Medical Research Center for Children's Health, Moscow, Russia.; Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia.; Central State Medical Academy of the Presidential Administration of the Russian Federation, Moscow, Russia.; Research Institute for Pediatrics and Children's Health Protection, Federal National Public Healthcare Institution 'Central Clinical Hospital of the Russian Academy of Sciences', Ministry of Science and Higher Education, Moscow, Russia., Namazova-Baranova LS; Research Institute for Pediatrics and Children's Health Protection, Federal National Public Healthcare Institution 'Central Clinical Hospital of the Russian Academy of Sciences', Ministry of Science and Higher Education, Moscow, Russia.; Pirogov Russian National Research Medical University, Moscow, Russia., Makarova SG; National Medical Research Center for Children's Health, Moscow, Russia., Ivanov RA; National Medical Research Center for Children's Health, Moscow, Russia., Grigorev SG; Kirov Military Medical Academy, St Petersburg, Russia.; Pediatric Infectious Disease Clinical Research Center of the Federal Medical Biological Agency, St Petersburg, Russia., Fedorov DV; National Medical Research Center for Children's Health, Moscow, Russia., Ambarchian ET; National Medical Research Center for Children's Health, Moscow, Russia.; Research Institute for Pediatrics and Children's Health Protection, Federal National Public Healthcare Institution 'Central Clinical Hospital of the Russian Academy of Sciences', Ministry of Science and Higher Education, Moscow, Russia., Epishev RV; National Medical Research Center for Children's Health, Moscow, Russia.; Research Institute for Pediatrics and Children's Health Protection, Federal National Public Healthcare Institution 'Central Clinical Hospital of the Russian Academy of Sciences', Ministry of Science and Higher Education, Moscow, Russia., Materikin AI; National Medical Research Center for Children's Health, Moscow, Russia., Opryatin LA; National Medical Research Center for Children's Health, Moscow, Russia., Savelova AA; National Medical Research Center for Children's Health, Moscow, Russia.
Jazyk:	angličtina
Zdroj:	Frontiers in pediatrics [Front Pediatr] 2023 Apr 25; Vol. 11, pp. 1102354. Date of Electronic Publication: 2023 Apr 25 (Print Publication: 2023).
DOI:	10.3389/fped.2023.1102354
Abstrakt:	Introduction: Epidermal barrier dysfunction in children with atopic dermatitis can cause transcutaneous sensitization to allergens and allergic diseases. We evaluated the effectiveness of an early-intervention algorithm for atopic dermatitis treatment, utilizing pimecrolimus for long-term maintenance therapy, in reducing transcutaneous sensitization in infants. Method: This was a single-center cohort observational study that enrolled children aged 1-4 months with family history of allergic diseases, moderate-to-severe atopic dermatitis, and sensitization to ≥ 1 of the investigated allergens. Patients who sought medical attention at atopic dermatitis onset (within 10 days) were group 1 "baseline therapy with topical glucocorticoids with subsequent transition to pimecrolimus as maintenance therapy"; patients who sought medical attention later were group 2 "baseline and maintenance therapy with topical glucocorticoids, without subsequent use of pimecrolimus". Sensitization class and level of allergen-specific immunoglobulin E were determined at baseline, and 6 and 12 months of age. Atopic dermatitis severity was evaluated using the Eczema Area and Severity Index score at baseline and 6, 9 and 12 months of age. Results: Fifty-six and 52 patients were enrolled in groups 1 and 2, respectively. Compared with group 2, group 1 demonstrated a lower level of sensitization to cow's milk protein, egg white and house dust mite allergen at 6 and 12 months of age, and a more pronounced decrease in atopic dermatitis severity at 6, 9 and 12 months of age. No adverse events occurred. Discussion: The pimecrolimus-containing algorithm was effective in treating atopic dermatitis and prophylaxis of early forms of allergic diseases in infants. Trial Registration: https://clinicaltrials.gov/ NCT04900948, retrospectively registered, 25 May 2021. Competing Interests: NNM reports grants and personal fees from Jansen, grants from Eli Lilly, grants and personal fees from Novartis, personal fees from Galderma, personal fees from Pierre Fabre, personal fees from Bayer, personal fees from Leofarma, grants and personal fees from Pfizer, grants and personal fees from AbbVie, grants from Amryt Pharma, personal fees and non-financial support from Viatris, outside the submitted work; LSN reports grants and personal fees from MSD Pharmaceuticals LLC, grants and personal fees from FORT LLC, grants and personal fees from Shire Biotech Rus LLC, grants and personal fees from Pfizer Innovations LLC, grants and personal fees from Sanofi Aventis Group LLC, grants and personal fees from AbbVie LLC, grants and personal fees from Pierre Fabre LLC, outside the submitted work; SGM reports grants and personal fees from Nutricia, grants and personal fees from FrieslandCampina, outside the submitted work; ETA reports personal fees from Eli Lilly, personal fees from Novartis, personal fees from AbbVie, personal fees from Jansen, personal fees from Amryt Pharma, outside the submitted work; RVE reports personal fees from Eli Lilly, personal fees from Novartis, personal fees from AbbVie, personal fees from Amryt Pharma, outside the submitted work; AIM reports personal fees from Eli Lilly, personal fees from Novartis, personal fees from AbbVie, personal fees from Amryt Pharma, outside the submitted work. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construes as a potential conflict of interest. (© 2023 Murashkin, Namazova-Baranova, Makarova, Ivanov, Grigorev, Fedorov, Ambarchian, Epishev, Materikin, Opryatin and Savelova.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu